These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38802165)

  • 1. Intraintestinal Heterogeneity of Drug Target Expression in Inflammatory Bowel Disease.
    Swanson K; Younes M
    Ann Clin Lab Sci; 2024 Mar; 54(2):156-159. PubMed ID: 38802165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
    Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
    Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changing paradigm in the management of inflammatory bowel disease].
    Jang BI
    Korean J Gastroenterol; 2015 May; 65(5):268-72. PubMed ID: 25998972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal Inflammation Modulates the Epithelial Response to Butyrate in Patients With Inflammatory Bowel Disease.
    Ferrer-Picón E; Dotti I; Corraliza AM; Mayorgas A; Esteller M; Perales JC; Ricart E; Masamunt MC; Carrasco A; Tristán E; Esteve M; Salas A
    Inflamm Bowel Dis; 2020 Jan; 26(1):43-55. PubMed ID: 31211831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of direct tissue isoelectric focused protein profiles of resected intestinal mucosa and endoscopic biopsies from patients with inflammatory bowel disease.
    Szewczuk MR; Depew WT
    Clin Invest Med; 1992 Feb; 15(1):49-59. PubMed ID: 1374000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localization of TNF alpha in ileocolonic biopsies of patients with inflammatory bowel disease.
    Villanacci V; Cadei M; Lanzarotto F; Ricci C; Antonelli E; Cannatelli R; Gulotta T; Fontana L; Pasquali V; Sigala S; Salviato T; Nascimbeni R; Bassotti G
    Ann Diagn Pathol; 2019 Feb; 38():20-25. PubMed ID: 30388432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease.
    Tang R; Yang G; Zhang S; Wu C; Chen M
    Inflamm Bowel Dis; 2014 Nov; 20(11):1950-61. PubMed ID: 25208103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus, inflammatory bowel disease, and anti-TNFα.
    Campos ST; Portela FA; Tomé L
    Int J Colorectal Dis; 2017 May; 32(5):645-650. PubMed ID: 28084548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
    Molander P; Färkkilä M; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
    Inflamm Bowel Dis; 2014 Jun; 20(6):1021-8. PubMed ID: 24798636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease.
    Breese EJ; Michie CA; Nicholls SW; Murch SH; Williams CB; Domizio P; Walker-Smith JA; MacDonald TT
    Gastroenterology; 1994 Jun; 106(6):1455-66. PubMed ID: 8194690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of Na+/H+ exchanger isoform-3 in human inflammatory bowel disease: lack of reversal by 5'-aminosalicylate treatment.
    Siddique I; Hasan F; Khan I
    Scand J Gastroenterol; 2009; 44(1):56-64. PubMed ID: 18785066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease.
    Vavricka SR; Galván JA; Dawson H; Soltermann A; Biedermann L; Scharl M; Schoepfer AM; Rogler G; Prinz Vavricka MB; Terracciano L; Navarini A; Zlobec I; Lugli A; Greuter T
    J Crohns Colitis; 2018 Feb; 12(3):347-354. PubMed ID: 29182760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal Epithelial Cells Express Immunomodulatory ISG15 During Active Ulcerative Colitis and Crohn's Disease.
    Østvik AE; Svendsen TD; Granlund AVB; Doseth B; Skovdahl HK; Bakke I; Thorsvik S; Afroz W; Walaas GA; Mollnes TE; Gustafsson BI; Sandvik AK; Bruland T
    J Crohns Colitis; 2020 Jul; 14(7):920-934. PubMed ID: 32020185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in MAdCAM1-Positive Mucosal Capillaries and Integrin a4b7-Positive Lymphocytes in Crohn's Disease Treated with Anti-TNFα Biologics.
    Younes M; DuPont AW; Cash BD; Ertan A
    Ann Clin Lab Sci; 2021 Sep; 51(5):678-685. PubMed ID: 34686510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis.
    Tanaka M; Riddell RH; Saito H; Soma Y; Hidaka H; Kudo H
    Scand J Gastroenterol; 1999 Jan; 34(1):55-67. PubMed ID: 10048734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease.
    Woywodt A; Ludwig D; Neustock P; Kruse A; Schwarting K; Jantschek G; Kirchner H; Stange EF
    Eur J Gastroenterol Hepatol; 1999 Mar; 11(3):267-76. PubMed ID: 10333199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumor necrosis factor alpha therapy.
    Hlavaty T; Krajcovicova A; Letkovsky J; Sturdik I; Koller T; Toth J; Huorka M
    Bratisl Lek Listy; 2016; 117(4):205-11. PubMed ID: 27075383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients.
    De Felice KM; Novotna M; Enders FT; Faubion WA; Tremaine WJ; Kantarci OH; Raffals LE
    Aliment Pharmacol Ther; 2015 Jan; 41(1):99-107. PubMed ID: 25348720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.